Odyssey Therapeutics, Inc. (ODTX)
Health Care · Clinical-stage biotechnology · NASDAQ
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
What Odyssey Therapeutics, Inc. does
Odyssey Therapeutics is a clinical-stage biotechnology company focused on developing novel product candidates through preclinical research and clinical trials. The company's lead programs include OD-001 (currently in phase 2a clinical trial) and OD-002 (in IND-enabling studies). The company has no approved products, has never generated revenue from product sales, and relies on capital raises to fund its drug development operations.
Themes: drug discovery and development, clinical-stage biotech
Fundamentals
- Price$25.62 as of 2026-08-26 close
- Market cap$1.2B as of 2026-08-26
- P/En/a negative earnings
- Net margin-3822.7% as of 2026-08-27
- ROE-69.0% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Revenue growth (YoY)-19.0% as of 2026-08-27
- Beta-0.15 as of 2026-08-27
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How ODTX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-27
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-27
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-27
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Odyssey Therapeutics, Inc. looks technically
Odyssey Therapeutics, Inc. (ODTX): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.45 | $19.45 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with buyers in control | 47.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($19.84 to $28.00) — its "stochastic" reading is 71 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 70.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 28 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.00 | $28.00 |
|---|---|---|
| From the 52-week high | it is 8.5% below its 52-week high (its highest price of the past year) | -8.5% |
| Above the 52-week low | it is 69.7% above its 52-week low (its lowest price of the past year) | +69.7% |
| Below the 52-week high | it is 8.5% below its highest point of the past year | 8.5% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $28.00 (set on 2026-08-24) | $28.00 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 8.5% below its all-time high | -8.5% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $15.10 (set on 2026-07-08) | $15.10 |
| Above the all-time low | it is 69.7% above its all-time low | +69.7% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.86 between its high and its low — about 7.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.86 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.02 and $26.95 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.02 – $21.99 – $26.95 |
| Typical daily range (% of price) | its price moves about 7.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.3% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 5 sessions ago and has not traded back through the level it left behind at 21.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 3.1% gap up opened on 2026-08-14 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 33.6 percentage points (the stock gained 37.3% while the market gained 3.7%) | +33.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 43.7 percentage points (the stock gained 46.4% while the market gained 2.7%) | +43.7% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 5 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 5 |
|---|---|---|
| Bearish technical signals | 0 of the 5 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 5 |
Volume-weighted price
2
| Vs this year’s average price paid | the price is 41% above the average price paid since 2026-05-08, so the typical buyer over that stretch is showing a gain. That average is $18.15 — a volume-weighted average of daily closes over 66 sessions, not a true tick-by-tick VWAP. | +41.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $23.08 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +11.0% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: in a strong, established uptrend (ADX) · Most volatile (6%+ typical daily range) | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$33.00 range $29.00 – $40.00; median $30.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ODTX
- Consensus EPS estimate-$0.9302 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Limited operating history with a history of substantial net losses and no commercialized products.","Significant capital requirements to fund ongoing research and drug development programs.","Dependence on the successful clinical development and regulatory approval of a small portfolio of product candidates."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days9 buys ($75M) · 3 sells ($32040) — 7 buying, 1 selling insiders
Cluster buying: 7 different insiders reported open-market purchases (SEC code P) of ODTX within a 30-day window between 2026-05-08 and 2026-05-11. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-11. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ODTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ODTX had 2,270,930 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ODTX had 4.73% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.68 days to cover at the same settlement.
- Reported short interest (shares) 2,270,930
- Short interest (% of shares outstanding) 4.73%
- Prior settlement (shares) 1,993,860
- Reported change 13.9%
- Days to cover (reported) 9.68
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Odyssey Therapeutics, Inc. is found in…
Frequently asked questions
What does Odyssey Therapeutics, Inc. (ODTX) do?
Odyssey Therapeutics is a clinical-stage biotechnology company focused on developing novel product candidates through preclinical research and clinical trials. The company's lead programs include OD-001 (currently in phase 2a clinical trial) and OD-002 (in IND-enabling studies). The company has no approved products, has never generated revenue from product sales, and relies on capital raises to fund its drug development operations.
What sector is Odyssey Therapeutics, Inc. (ODTX) in?
Odyssey Therapeutics, Inc. (ODTX) is classified in the Health Care sector. Its industry is Clinical-stage biotechnology. It trades on NASDAQ.
Is Odyssey Therapeutics, Inc. (ODTX) overbought or oversold right now?
Odyssey Therapeutics, Inc. (ODTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ODTX come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.